Pfizer Inc (UKEX:PFE) Stock Price, Trades & News

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.21
Equity-to-Asset	0.43
Debt-to-Equity	0.71
Debt-to-EBITDA	3.71
Interest Coverage	6.42
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.02	Distress Grey Safe
Beneish M-Score	-2.32	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

3/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-14.7
	3-Year EBITDA Growth Rate	-25.7
	3-Year EPS without NRI Growth Rate	-21.2
	3-Year FCF Growth Rate	-29.5
	3-Year Book Growth Rate	-3.7
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	-8.73
	Future 3-5Y Total Revenue Growth Rate Estimate	-4.35

Momentum Rank

7/10

	Name	Current	Vs Industry		Vs History

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.25
	Quick Ratio	0.94
	Cash Ratio	0.38
	Days Inventory	240.77
	Days Sales Outstanding	72.23
	Days Payable	109.59

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Payout Ratio	0.56
	3-Year Dividend Growth Rate	2.4
	3-Year Average Share Buyback Ratio	-0.4
	Shareholder Yield %	9.14

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	73.51
	Operating Margin %	27.24
	Net Margin %	11.83
	EBITDA Margin %	27.13
	FCF Margin %	14.98
	OCF Margin %	18.93
	ROE %	8.35
	ROA %	3.61
	ROIC %	8.62
	3-Year ROIIC %	-121.21
	ROC (Joel Greenblatt) %	55.91
	ROCE %	6.18
	Years of Profitability over Past 10-Year	10
	Moat Score	8
	Tariff Resilience Score	6

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	18.37
	Forward PE Ratio	7.71
	PE Ratio without NRI	7.83
	Shiller PE Ratio	8.48
	Price-to-Owner-Earnings	28.02
	PS Ratio	2.17
	PB Ratio	1.52
	Price-to-Free-Cash-Flow	14.53
	Price-to-Operating-Cash-Flow	11.49
	EV-to-EBIT	17.76
	EV-to-Forward-EBIT	11.84
	EV-to-EBITDA	10.95
	EV-to-Forward-EBITDA	9.84
	EV-to-Revenue	2.97
	EV-to-Forward-Revenue	3.58
	EV-to-FCF	19.84
	Price-to-GF-Value	0.92
	Price-to-Projected-FCF	0.64
	Price-to-Median-PS-Value	0.58
	Earnings Yield (Greenblatt) %	5.63
	FCF Yield %	6.91
	Forward Rate of Return (Yacktman) %	-2.93

Financials (Next Earnings Date:2026-08-05 Est.)

Annual Quarterly TTM

UKEX:PFE's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Pfizer Inc Executives

Details

GF Value™: ₴1096.57

UKEX:PFE

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with PFE. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil ₴)	2,818,502.74
	EPS (TTM) (₴)	58.316
	Beta	-
	3-Year Sharpe Ratio	-
	3-Year Sortino Ratio	-
	Volatility %	3.11
	14-Day RSI	-
	14-Day ATR (₴)	-
	20-Day SMA (₴)	1014
	12-1 Month Momentum %	-
	52-Week Range (₴)	1014 - 1014
	Shares Outstanding (Mil)	5,699.44

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Pfizer Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Pfizer Inc Stock Events

Financials Calendars

Event	Date	Price (₴)
Third quarter earnings conference call for 2026	2026-11-04 10:00	In 120 days
Third quarter earnings results for 2026	2026-11-04	In 119 days
Second quarter earnings conference call for 2026	2026-08-05 10:00	In 29 days
Second quarter earnings results for 2026	2026-08-05	In 28 days
conference call with investment analysts	2026-08-04 10:00	In 28 days
USD 0.430000 Cash Dividend	2026-07-24	In 16 days
Jefferies Global Healthcare Conference	2026-06-03 14:00	1,014.00 (+0.00%)
USD 0.430000 Cash Dividend	2026-05-11	1,014.00 (+0.00%)
First quarter earnings conference call for 2026	2026-05-05 10:00	1,014.00 (+0.00%)
First quarter earnings results for 2026	2026-05-05	1,014.00 (+0.00%)

Show

Entries

Pfizer Inc Frequently Asked Questions

What is Pfizer Inc(UKEX:PFE)'s stock price today?

The current price of UKEX:PFE is ₴1014.00. The 52 week high of UKEX:PFE is ₴1014.00 and 52 week low is ₴1014.00.

When is next earnings date of Pfizer Inc(UKEX:PFE)?

The next earnings date of Pfizer Inc(UKEX:PFE) is 2026-08-05 Est..

Does Pfizer Inc(UKEX:PFE) pay dividends? If so, how much?

Pfizer Inc(UKEX:PFE) does not pay dividend.

Press Release

	Subject	Date
	Pfizer Declares Third-Quarter 2026 Dividend	2026-06-24
	FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance	2026-06-24
	Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts	2026-06-23
	Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer	2026-06-22
	U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need	2026-06-08
	Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide	2026-06-06
	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference	2026-06-01
	Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer	2026-05-31
	TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer	2026-05-30
	Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer	2026-05-29

10/Page

Articles on Pfizer Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.